Key result
Vasostatin specifically binds to laminin and inhibits endothelial cell attachment, reducing subsequent endothelial cell growth induced by basic fibroblast growth factor.
Vasostatin acts as an angiogenesis inhibitor by specifically disrupting endothelial cell attachment to laminin, highlighting its potential as a cancer therapeutic.
Hypothesis-generating for vasostatin in angiogenesis inhibition; prospective studies needed before any therapeutic consideration.
Vasostatin, the 1-180 amino acids NH(2) domain of calreticulin, inhibits endothelial cell proliferation, angiogenesis, and tumor growth, but the mechanisms underlying these effects are unclear. We show that endothelial cells express the extracellular matrix protein laminin, including chains alpha 5 and gamma 1 and that vasostatin specifically binds to laminin. When added to endothelial cell cultures, vasostatin specifically inhibits endothelial cell attachment to laminin and by this mechanism, can reduce subsequent endothelial cell growth induced by basic fibroblast growth factor. As an angiogenesis inhibitor that specifically disrupts endothelial cell attachment to components of the extracellular matrix, vasostatin has a unique potential as a cancer therapeutic.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2002) studied Angiogenesis and tumor growth. Vasostatin was evaluated on Endothelial cell attachment to laminin and subsequent growth. Vasostatin specifically binds to laminin and inhibits endothelial cell attachment, reducing subsequent endothelial cell growth induced by basic fibroblast growth factor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: